Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Chimerix is a biotechnology business based in the US. Chimerix shares (CMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Chimerix employs 87 staff and has a trailing 12-month revenue of around $33.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $1.82 |
|---|---|
| 52-week range | $1.27 - $6.43 |
| 50-day moving average | $1.98 |
| 200-day moving average | $2.29 |
| Wall St. target price | $7.50 |
| PE ratio | 1.0643 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.71 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.82 from 2023-02-03
| 1 week (2023-01-31) | 2.82% |
|---|---|
| 1 month (2023-01-06) | -2.67% |
| 3 months (2022-11-07) | -6.19% |
| 6 months (2022-08-05) | -32.09% |
| 1 year (2022-02-03) | N/A |
|---|---|
| 2 years (2021-02-05) | -81.31% |
| 3 years (2020-02-07) | 7.69% |
| 5 years (2018-02-07) | 4.93 |
Valuing Chimerix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Chimerix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Chimerix's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Chimerix shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $33.1 million |
|---|---|
| Gross profit TTM | $-71,838,000 |
| Return on assets TTM | -22.26% |
| Return on equity TTM | 81.17% |
| Profit margin | 464.75% |
| Book value | $3.11 |
| Market capitalisation | $160.2 million |
TTM: trailing 12 months
We're not expecting Chimerix to pay a dividend over the next 12 months.
Over the last 12 months, Chimerix's shares have ranged in value from as little as $1.27 up to $6.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chimerix's is 1.1821. This would suggest that Chimerix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Chimerix, Inc. , a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.